Important note: Information in this article was accurate in July 2008. The state of the art may have changed since the publication date.
DSMB stops ACTG study due to suboptimal responses
HIV Treat Bull - 2008 July-August;9(7/8):
An independent Data and Safety Monitoring Board (DSMB) has determined that the experimental, once-daily antiretroviral drug regimen of FTC (emtricitabine), atazanavir and ddI enteric-coated (ddI-EC) is inferior to a standard antiretroviral drug regimen and therefore should be discontinued in an ongoing clinical trial. The National Institute of Allergy and Infectious Diseases (NIAID), the part of the National Institutes of Health that oversees the trial, concurs with this recommendation and has stopped this component of the study.
This development arose from the DSMB’s recent review of safety and efficacy data from a Phase IV clinical trial sponsored by NIAID. The trial is examining whether certain regimens of antiretrovirals taken once a day are at least as good as a standard antiretroviral regimen containing a drug combination taken twice a day. The study involves 1,571 HIV-infected volunteers on four continents who were randomly assigned to take one of three drug regimens:
The DSMB found conclusive evidence that the second regimen, FTC + atazanavir + ddI-EC, is inferior to the control regimen primarily because it is less effective at controlling HIV. Based on this finding, the decision has been made to discontinue the emtricitabine + atazanavir + ddI-EC component of the study. All study participants are being notified of the development.
comment
It is unclear why anyone would have expected FTC/ddI/un-boosted atazanavir to work as well as boosted - and what would be the advantage to someone risking this.
The press statement uses psuedo-medical language as if everything is so reasonable, eg ‘NIAID concurs with DSMB’ - they have no choice and certainly couldn’t go against a DSMB recommendation; or using ‘conclusive evidence’ rather than just say ‘the study found’.
More critically, the ddI and atazanavir interaction should have been sufficient for this not to have been studied - especially with unboosted atazanavir. It is also difficult to see how option 2 is a once-daily regimen if it required separating the ddI and atazanavir doses.
Source:
NIAID press release: Monitoring Board Recommends Stopping Experimental Treatment Regimen in International Study of Patients New to HIV Treatment.
For more information on this announcement
2008-07-10
IB080907-15
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.